Estrella Immunopharma, Inc. announced a $8.0 million registered direct offering and a concurrent private placement.
The offering includes shares of common stock and pre-funded warrants to a healthcare-focused institutional investor.
The transactions are expected to close on or about January 6, 2026.
Estrella Immunopharma's strategic move to offer registered direct offerings and private placements indicates a focus on financial growth and expansion.
Transaction Details
Comprised of Common Units and PIPE Common Warrants, priced at $1.58 per Common Unit.
Placement Agents
Aegis Capital Corp. is the exclusive placement agent for the offerings.
Legal Counsel
Winston & Strawn LLP represents the Company, and Sichenzia Ross Ference Carmel LLP represents Aegis Capital Corp.
- The transactions aim to raise funds for general corporate purposes and working capital.
- Estrella Immunopharma's strategic move to offer registered direct offerings and private placements indicates a focus on financial growth and expansion.
Estrella Immunopharma's recent financial offerings reflect a proactive approach to funding for future growth and operational needs.